Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

gilead sciences inc. - GILD

GILD

Close Chg Chg %
125.00 -2.38 -1.90%

Closed Market

122.62

-2.38 (1.90%)

Volume: 5.23M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: gilead sciences inc. - GILD

GILD Key Data

Open

$124.81

 Day Range

122.40 - 124.96

52 Week Range

88.58 - 128.70

 Market Cap

$155.09B

Shares Outstanding

1.24B

 Public Float

1.24B

Beta

0.33

 Rev. Per Employee

N/A

P/E Ratio

19.19

 EPS

$6.51

Yield

253.41%

 Dividend

$0.79

EX-DIVIDEND DATE

Dec 15, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.06M

  

GILD Performance

1 Week
 
 -0.67%
 
1 Month
 
 5.18%
 
3 Months
 
 8.65%
 
1 Year
 
 35.68%
 
5 Years
 
 103.05%
 

GILD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About gilead sciences inc. - GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

GILD At a Glance

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
Phone 1-650-574-3000 Revenue 28.73B
Industry Biotechnology Net Income 480.00M
Sector Health Technology 2024 Sales Growth 6.168%
Fiscal Year-end 12 / 2025 Employees 17,600
View SEC Filings

GILD Valuation

P/E Current 19.192
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 241.49
Price to Sales Ratio 4.035
Price to Book Ratio 5.954
Price to Cash Flow Ratio 10.71
Enterprise Value to EBITDA 9.801
Enterprise Value to Sales 4.581
Total Debt to Enterprise Value 0.208

GILD Efficiency

Revenue/Employee 1,632,215.909
Income Per Employee 27,272.727
Receivables Turnover 6.499
Total Asset Turnover 0.474

GILD Liquidity

Current Ratio 1.597
Quick Ratio 1.455
Cash Ratio 0.964

GILD Profitability

Gross Margin 78.24
Operating Margin 37.108
Pretax Margin 2.402
Net Margin 1.671
Return on Assets 0.793
Return on Equity 2.277
Return on Total Capital 1.029
Return on Invested Capital 1.052

GILD Capital Structure

Total Debt to Total Equity 141.345
Total Debt to Total Capital 58.566
Total Debt to Total Assets 46.312
Long-Term Debt to Equity 131.371
Long-Term Debt to Total Capital 54.433
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Gilead Sciences Inc. - GILD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
27.37B 27.09B 27.06B 28.73B
Sales Growth
+11.08% -1.05% -0.10% +6.17%
Cost of Goods Sold (COGS) incl D&A
6.60B 5.66B 6.02B 6.25B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.05B 2.10B 2.69B 2.77B
Depreciation
329.00M 323.00M 354.00M 381.00M
Amortization of Intangibles
1.72B 1.78B 2.34B 2.39B
COGS Growth
+46.40% -14.30% +6.40% +3.85%
Gross Income
20.77B 21.43B 21.04B 22.48B
Gross Income Growth
+3.17% +3.16% -1.82% +6.83%
Gross Profit Margin
+75.88% +79.11% +77.76% +78.24%
2021 2022 2023 2024 5-year trend
SG&A Expense
10.57B 10.67B 11.29B 11.82B
Research & Development
5.36B 5.00B 5.76B 5.82B
Other SG&A
5.21B 5.67B 5.54B 6.00B
SGA Growth
+9.09% +0.96% +5.85% +4.61%
Other Operating Expense
- - - -
-
Unusual Expense
1.52B 4.21B 2.31B 9.26B
EBIT after Unusual Expense
8.68B 6.54B 7.44B 1.40B
Non Operating Income/Expense
600.00M 205.00M 366.00M 271.00M
Non-Operating Interest Income
- - 376.00M 281.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.00B 935.00M 944.00M 977.00M
Interest Expense Growth
+1.73% -6.59% +0.96% +3.50%
Gross Interest Expense
1.00B 935.00M 944.00M 977.00M
Interest Capitalized
- - - -
-
Pretax Income
8.28B 5.81B 6.86B 690.00M
Pretax Income Growth
+395.99% -29.77% +17.97% -89.94%
Pretax Margin
+30.24% +21.47% +25.35% +2.40%
Income Tax
2.08B 1.25B 1.25B 210.00M
Income Tax - Current - Domestic
2.00B 2.57B 1.86B 1.53B
Income Tax - Current - Foreign
185.00M 232.00M 381.00M 519.00M
Income Tax - Deferred - Domestic
(65.00M) (1.66B) (956.00M) (1.95B)
Income Tax - Deferred - Foreign
(47.00M) 101.00M (40.00M) 105.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.20B 4.57B 5.61B 480.00M
Minority Interest Expense
- (24.00M) (26.00M) (52.00M)
Net Income
6.22B 4.59B 5.67B 480.00M
Net Income Growth
+4,960.98% -26.23% +23.37% -91.53%
Net Margin Growth
+22.74% +16.95% +20.94% +1.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.22B 4.59B 5.67B 480.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
6.22B 4.59B 5.67B 480.00M
EPS (Basic)
4.9562 3.659 4.5393 0.3849
EPS (Basic) Growth
+4,962.51% -26.17% +24.06% -91.52%
Basic Shares Outstanding
1.26B 1.25B 1.25B 1.25B
EPS (Diluted)
4.9326 3.6387 4.5032 0.3825
EPS (Diluted) Growth
+4,964.27% -26.23% +23.76% -91.51%
Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.25B
EBITDA
12.25B 12.86B 12.44B 13.43B
EBITDA Growth
+2.74% +4.97% -3.29% +7.96%
EBITDA Margin
+44.76% +47.48% +45.96% +46.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 132.435
Number of Ratings 31 Current Quarters Estimate 1.871
FY Report Date 12 / 2025 Current Year's Estimate 8.169
Last Quarter’s Earnings 2.47 Median PE on CY Estimate N/A
Year Ago Earnings 4.62 Next Fiscal Year Estimate 8.714
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 20 7 25 25
Mean Estimate 1.87 2.05 8.17 8.71
High Estimates 2.08 2.19 8.43 9.50
Low Estimate 1.75 1.85 8.05 6.38
Coefficient of Variance 4.57 5.72 1.13 7.06

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 17
OVERWEIGHT 4 4 4
HOLD 9 9 9
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Gilead Sciences Inc. - GILD

Date Name Shares Transaction Value
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 73,110 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 107,193 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.26 per share 13,534,188.18
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 109,669 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.83 per share 13,799,650.27
Nov 20, 2025 Johanna Mercier Chief Commercial Officer 135,193 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $66.64 per share 9,009,261.52
Nov 20, 2025 Andrew D. Dickinson Chief Financial Officer 154,555 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.23 per share 19,354,922.65
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 42,721 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.2 per share 4,964,180.20
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 21,646 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 29,875 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 46,544 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Deborah H. Telman EVP, Corporate Affairs & GC 38,315 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 16, 2025 Jeffrey A. Bluestone Director 13,920 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $67.45 per share 938,904.00
Jul 16, 2025 Jeffrey A. Bluestone Director 8,920 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $109.74 per share 978,880.80
Jul 16, 2025 Jeffrey A. Bluestone Director 9,665 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 7, 2025 Sandra K. Patterson SVP, Controllership 37,787 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Daniel P. O'Day Chairman & CEO; Director 617,876 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.99 per share 60,545,669.24
Feb 7, 2025 Daniel P. O'Day Chairman & CEO; Director 726,032 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Daniel P. O'Day Chairman & CEO; Director 561,559 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Andrew D. Dickinson Chief Financial Officer 171,223 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.99 per share 16,778,141.77
Feb 7, 2025 Andrew D. Dickinson Chief Financial Officer 214,361 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Dietmar P. Berger Chief Medical Officer 48,975 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Gilead Sciences Inc. in the News

Inside the race for a COVID-19 treatment pill

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.

COVID-19 vaccine start-up files for IPO

The biotech startup behind the COVID-fox19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering. Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.